Penile Cancer
53
14
20
23
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.8%
2 terminated out of 53 trials
92.0%
+5.4% vs benchmark
2%
1 trials in Phase 3/4
35%
8 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 23 completed trials
Clinical Trials (53)
Linking In With Advice and Supports for Men Impacted by Metastatic Cancer
DEfeating PEnile CAncer-2
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer
Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile Cancer
Assessment of Patient Experience and Needs for Patients Undergoing Invasive Inguinal Lymph Node Procedures for Penile Cancer
EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy
A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy
Integrated Cancer Repository for Cancer Research
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
QL1706 Plus Lenvatinib in Previously Treated Penile Cancer
Lymphedema After Urologic Surgery
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
Ivonescimab in the Treatment of Multiple Advanced Tumors
A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER